Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bluejay Diagnostics, Inc. (BJDX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing insight into its development of the Symphony near-patient testing platform and Symphony IL-6 Test for sepsis triage and monitoring. As an emerging growth company listed on The Nasdaq Capital Market, Bluejay files periodic and current reports that describe its clinical, manufacturing, financing, and governance activities.
Through Forms 10-K and 10-Q, investors can review Bluejay’s descriptions of the Symphony System, its regulatory plans for a 510(k) submission for the Symphony IL-6 test, and discussions of risks, liquidity, and capital requirements. Current reports on Form 8-K detail material events such as amendments to the Master Service Agreement and Master Supply Agreement with SanyoSeiko Co., Ltd., changes to license and supply arrangements with Toray Industries, Inc., private placements of common stock, pre-funded warrants and Series F warrants, and the implementation of a 1-for-50 reverse stock split.
This page also provides access to exhibits referenced in Bluejay’s 8-K filings, including forms of warrants, securities purchase agreements, registration rights agreements, and amendments to key manufacturing and licensing contracts. These documents help explain how Bluejay is structuring its manufacturing partnerships, securing access to cartridge components, and arranging financing to support clinical trials and regulatory activities for the Symphony IL-6 test.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, such as how a particular financing affects share structure or how a contract amendment changes manufacturing responsibilities. Users can quickly identify disclosures related to capital raises, reverse stock splits, material agreements, and other events without reading every page of the underlying filing. Real-time updates from EDGAR ensure that new Bluejay filings, including any future proxy statements or insider transaction reports, are added as they become available, giving investors a structured view of BJDX’s regulatory history and ongoing obligations.
Investors affiliated with Intracoastal Capital report a 4.99% passive stake in Bluejay Diagnostics, Inc. As of December 31, 2025, Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC may be deemed to beneficially own 91,537 shares of common stock.
This amount includes 71,243 common shares held by Intracoastal and 20,294 shares issuable upon exercise of one warrant. Additional warrant shares are subject to 4.99% “blocker” provisions that prevent their exercise above that ownership level; without these blockers, beneficial ownership would total 821,312 shares. The filers certify the holdings are not for changing or influencing control.
Bluejay Diagnostics, Inc. has a new Schedule 13G filing showing that investor Braeden Lichti and Northstrive Fund II LP together hold a small ownership position in the company’s common stock.
Northstrive Fund II LP beneficially owns 11,000 shares of common stock, representing 1.55% of the class, with shared voting and dispositive power over all 11,000 shares. Braeden Lichti beneficially owns a total of 35,500 shares, or 5.01% of the outstanding common stock, including 24,500 shares over which he has sole voting and dispositive power and 11,000 shares over which he shares voting and dispositive power with Northstrive Fund II LP.
The percentages are based on 708,533 shares of Bluejay Diagnostics common stock outstanding as of January 29, 2026, as reported in a recent company filing. Lichti is identified as the Manager of Northstrive Fund II LP, linking the individual and fund holdings.
Bluejay Diagnostics, Inc. investor ownership has shifted, triggering a Schedule 13G disclosure. Investor Braeden Lichti reports beneficial ownership of 35,500 shares of Bluejay Diagnostics common stock, representing 5.01% of the outstanding shares.
Lichti holds 24,500 shares with sole voting and dispositive power and shares voting and dispositive power over an additional 11,000 shares held through Northstrive Fund II LP. Northstrive Fund II LP itself reports beneficial ownership of 11,000 shares, or 1.55% of the company’s common stock, all with shared voting and dispositive power. These percentages are based on 708,533 shares outstanding as of January 29, 2026.
Bluejay Diagnostics, Inc. implemented a 1-for-4 reverse stock split of its common stock, effective January 29, 2026. Every four pre-split shares were converted into one share, reducing issued and outstanding common shares from 2,834,133 to approximately 708,533.
The number of shares issuable upon exercise of prefunded warrants was reduced from 1,055,000 to 263,750, and all equity awards, warrants, and shares reserved under equity plans were adjusted proportionately. The par value, voting rights, and other terms of the common stock were unchanged.
No fractional shares are being issued; eligible stockholders will receive cash in lieu of fractions, based on a recent average closing price. Trading continues on the Nasdaq Capital Market under the symbol “BJDX” with a new CUSIP number, and the company’s transfer agent is handling the share exchange and book-entry adjustments.
Bluejay Diagnostics (BJDX) furnished an Item 7.01 Regulation FD Disclosure on Form 8-K. The company issued a press release providing a 2025 third quarter financial and corporate update, furnished as Exhibit 99.1.
The information in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and is not incorporated by reference unless specifically identified. This update follows the company’s Form 10-Q for the quarter ended September 30, 2025, filed on November 7, 2025.
Bluejay Diagnostics filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $1,597,632 for the quarter and $5,418,671 for the nine-month period. Operating expenses were $1,616,947 in the quarter, led by research and development of $785,608 and general and administrative of $831,339.
Cash and cash equivalents were $3,082,268 with current liabilities of $1,148,913, and accumulated deficit reached $40,087,455. Management states that these results, combined with expected negative cash flows, raise substantial doubt about the company’s ability to continue as a going concern. A private placement in October 2025 generated ~$4.5 million gross proceeds, and the company estimates its cash resources can fund operations into the third quarter of 2026.
Bluejay continues developing its Symphony IL-6 test for sepsis, advancing the SYMON-II pivotal study with approximately half of the targeted enrollment achieved by quarter-end. The company expects to need to raise at least $20 million through 2027 to complete manufacturing redevelopment, clinical work, and prepare a 510(k) submission targeted for 2027.
Bluejay Diagnostics (BJDX) filed a resale registration covering up to 6,930,000 shares of common stock. The shares may be sold from time to time by the selling stockholders identified in the prospectus. The registered shares consist of 175,000 PIPE Shares, 2,075,000 shares issuable upon exercise of Pre-Funded Warrants, 4,500,000 shares issuable upon exercise of Series F Warrants, and 180,000 shares issuable upon exercise of Placement Agent Warrants, all issued in October 2025.
The company is not selling shares in this offering and will not receive proceeds from any resale by the selling stockholders. Bluejay will receive net proceeds only if warrants are exercised for cash. The common stock trades on Nasdaq as “BJDX”; the closing price was $2.56 per share on October 21, 2025. Certain warrants contain beneficial ownership limits of 4.99% or 9.99%, which cap exercises that would exceed those thresholds.
Bluejay Diagnostics entered into a private placement that closed on October 10, 2025, selling 175,000 shares of common stock and pre-funded warrants for up to 2,075,000 shares, together with Series F warrants for up to 4,500,000 shares. The combined price was $2.00 per share (or pre-funded warrant) plus accompanying Series F warrants to acquire two shares. The company received approximately $4.0 million in proceeds after fees.
Pre-funded warrants are immediately exercisable at $0.0001 per share and expire once exercised. Series F warrants are immediately exercisable at $1.75 per share and expire five and one-half years from issuance. The placement agent received warrants to purchase up to 180,000 shares, with an exercise price equal to 125% of the combined price per share and Series F warrants sold.
Bluejay agreed to register for resale the 175,000 shares and 6,755,000 warrant shares, file by October 24, 2025, and keep the registration effective until the registered shares may be sold under Rule 144. Issuances are restricted for 90 days after effectiveness, and certain variable-rate deals and splits are limited for one year. Warrant exercises are capped at 4.99% or 9.99% beneficial ownership, subject to notice-based adjustments.
Bluejay Diagnostics, Inc. entered into an amendment on October 3, 2025 to its existing Master Service Agreement and Master Supply Agreement with Sanyoseiko Co., Ltd.. The change is tied to Bluejay’s commercialization of its Symphony platform, a near-patient testing system designed to provide rapid results for biomarkers such as IL-6 used in sepsis management.
Under the amended arrangements, Sanyoseiko will provide end-to-end support for the Symphony platform. This includes supporting redevelopment of analyzers and cartridges with hardware, software, and design updates, managing raw material sourcing and vendor compliance, and acting as Bluejay’s contract manufacturer for analyzers, cartridges, and related components. Sanyoseiko will also handle fulfillment, kit assembly, labeling, packaging, shipping, and quality control, as well as regulatory and quality management support and equipment storage and maintenance. Bluejay also furnished a related press release as an exhibit.
Bluejay Diagnostics, Inc. reported that its Board of Directors updated leadership roles on the Board and its key committees, effective August 15, 2025. Donald R. Chase was appointed Chairperson of the Board, succeeding Douglas C. Wurth. Mr. Wurth became Chairperson of the Nominating and Corporate Governance Committee, succeeding Fred S. Zeidman, and Mr. Zeidman was named Chairperson of the Compensation Committee, succeeding Mr. Chase.
Mr. Chase continues to serve as Chairperson of the Audit Committee, and all three standing Board committees remain composed of Messrs. Chase, Wurth, and Zeidman. The Board describes these changes as part of its periodic review of governance assignments and notes that all three directors are considered independent under Nasdaq listing rules and Rule 10A-3 under the Securities Exchange Act of 1934.